Total Payments
$970.71
2024 Payments
$393.79
Companies
12
Transactions
23
Medicare Patients
4,758
Medicare Billing
$538,326
Payment Breakdown by Category
Food & Beverage$605.44 (62.4%)
Consulting$350.00 (36.1%)
Education$15.27 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $605.44 | 21 | 62.4% |
| Consulting Fee | $350.00 | 1 | 36.1% |
| Education | $15.27 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $350.00 | 1 | $0 (2018) |
| UCB, Inc. | $166.66 | 1 | $0 (2024) |
| ABBVIE INC. | $75.66 | 3 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $73.07 | 4 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $59.01 | 3 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $47.98 | 2 | $0 (2024) |
| Incyte Corporation | $47.19 | 2 | $0 (2024) |
| Lilly USA, LLC | $37.03 | 2 | $0 (2023) |
| PFIZER INC. | $35.03 | 2 | $0 (2024) |
| Amgen Inc. | $30.50 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $393.79 | 10 | UCB, Inc. ($166.66) |
| 2023 | $34.62 | 2 | Lilly USA, LLC ($19.35) |
| 2020 | $78.72 | 4 | AbbVie Inc. ($22.32) |
| 2019 | $93.00 | 5 | Regeneron Healthcare Solutions, Inc. ($33.32) |
| 2018 | $370.58 | 2 | Eli Lilly and Company ($350.00) |
All Payment Transactions
23 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/22/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $27.66 | General |
| 10/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $30.50 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $24.90 | General |
| Category: Dermatology | ||||||
| 08/27/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: DERMATOLOGY | ||||||
| 07/30/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: Dermatology | ||||||
| 05/30/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | Cabtreo (Drug), JUBLIA, ARAZLO | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Dermatology | ||||||
| 05/29/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $34.82 | General |
| Category: IMMUNOLOGY | ||||||
| 04/30/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.29 | General |
| Category: Dermatology | ||||||
| 01/08/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $166.66 | General |
| Category: Immunology | ||||||
| 10/12/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $19.35 | General |
| 04/10/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 12/01/2020 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: IMMUNOLOGY | ||||||
| 02/24/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/04/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $14.95 | General |
| Category: Dermatology | ||||||
| 01/21/2020 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2019 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Immunology | ||||||
| 05/08/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/23/2019 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $23.48 | General |
| Category: Dermatology | ||||||
| 02/06/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/15/2019 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: Immunology | ||||||
| 10/09/2018 | Sun Pharmaceutical Industries Inc. | ILUMYA (tildrakizumab-asmn) injection (Biological) | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: Dermatology | ||||||
| 01/26/2018 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,296 | 2,729 | $504,175 | $152,209 |
| 2022 | 12 | 1,219 | 2,676 | $472,260 | $144,271 |
| 2021 | 10 | 1,163 | 2,628 | $441,878 | $139,528 |
| 2020 | 10 | 1,080 | 2,270 | $357,123 | $102,318 |
Total Patients
4,758
Total Services
10,303
Medicare Billing
$538,326
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 267 | 473 | $172,172 | $51,375 | 29.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 218 | 301 | $74,347 | $22,314 | 30.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 223 | 379 | $72,520 | $18,998 | 26.2% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 118 | 156 | $43,724 | $18,145 | 41.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 128 | 162 | $55,800 | $15,011 | 26.9% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 181 | 1,055 | $22,155 | $7,532 | 34.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 31 | 40 | $17,736 | $5,277 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 23 | $11,247 | $4,010 | 35.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 13 | 20 | $10,340 | $3,505 | 33.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 47 | 65 | $15,665 | $3,372 | 21.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 49 | 55 | $8,470 | $2,671 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 245 | 448 | $158,144 | $48,590 | 30.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 211 | 313 | $75,120 | $23,466 | 31.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 218 | 360 | $71,280 | $18,530 | 26.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 96 | 132 | $34,840 | $14,567 | 41.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 125 | 157 | $50,832 | $14,356 | 28.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 169 | 1,066 | $22,386 | $7,696 | 34.4% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 28 | 33 | $13,845 | $4,398 | 31.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 40 | 65 | $14,820 | $3,397 | 22.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 14 | 21 | $10,647 | $3,387 | 31.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 16 | 18 | $8,550 | $2,920 | 34.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 45 | 51 | $7,548 | $2,206 | 29.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $4,248 | $756.72 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 258 | 460 | $157,780 | $50,974 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 211 | 281 | $65,473 | $22,212 | 33.9% |
About Dr. Julie Letsinger, MD
Dr. Julie Letsinger, MD is a Dermatology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871541565.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Julie Letsinger, MD has received a total of $970.71 in payments from pharmaceutical and medical device companies, with $393.79 received in 2024. These payments were reported across 23 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($605.44).
As a Medicare-enrolled provider, Letsinger has provided services to 4,758 Medicare beneficiaries, totaling 10,303 services with total Medicare billing of $538,326. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Palo Alto, CA
- Active Since 05/04/2006
- Last Updated 11/10/2011
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1871541565
Products in Payments
- Bimzelx (Biological) $166.66
- DUPIXENT (Biological) $73.07
- SKYRIZI (Biological) $57.14
- OPZELURA (Drug) $47.19
- ILUMYA (Biological) $38.43
- Otezla (Drug) $30.50
- COSENTYX (Drug) $27.56
- Cabtreo (Drug) $20.92
- ILUMYA (tildrakizumab-asmn) injection (Biological) $20.58
- COSENTYX (Biological) $20.42
- EUCRISA (Drug) $19.76
- Humira (Biological) $18.52
- TALTZ (Drug) $17.68
- CIBINQO (Drug) $15.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Palo Alto
John Doux, M.d, M.D
Dermatology — Payments: $124,944
Dermatology $124,944
Joyce Teng, Md, MD
Dermatology — Payments: $115,109
Dermatology $115,109
Shireen Guide, Md, MD
Dermatology — Payments: $79,371
Dermatology $79,371
Ilka Netravali, Md, MD
Dermatology — Payments: $28,025
Dermatology $28,025
Dr. Daniel Navi, M.d, M.D
Dermatology — Payments: $19,065
Dermatology $19,065
Dr. Thomas Hoffman, M.d, M.D
Dermatology — Payments: $17,860
Dermatology $17,860